Jason has spent the past 16 years on Wall Street as an analyst both managing biotechnology dedicated investments (buy-side) and covering stem cell companies (sell-side). Prior to his career on Wall Street he spent several years in the pharmaceutical industry with Schering-Plough in Japan where he developed an extensive working knowledge of pharmaceutical operations in Asia. Jason has a degree in Chemistry and an MBA in Finance (University of New Haven).
- Jason was formerly a managing director of National Securities where he founded the firm’s research effort in emerging biotechnology companies. Jason’s coverage universe has been focused on cell therapeutic companies focused in oncology and regenerative medicine and NBS was just 1 of his covered companies.
The Bottom Lone: Jason’s working knowledge of the biotech and specifically the stem cell industry and experience in Asia coupled with his background in finance and solid track record on Wall Street should further align NBS growth. NBS will also be able to capitalize on his broad stem cell universe relationships and knowledge as NBS continues to evolve new therapeutics into a stronger product pipeline and product revenues. I believe his strategic and bottom line focus will help unlock value for shareholders as paradigms shift cell-based approaches. Expect NBS’s share price to rise in the near term as his feet hit the ground!